Pharmacology of Estrogens and Gestagens 33

Total Page:16

File Type:pdf, Size:1020Kb

Pharmacology of Estrogens and Gestagens 33 MENOPAUSE ANDROPAUSE Pharmacology of Estrogens and Gestagens 33 PHARMACOLOGY OF ESTROGENS AND GESTAGENS H. KUHL Replacement therapy with estrogens for osteoporosis prevention, and it does and gestagens serves the purpose of not have any effect on the lipid meta­ avoiding the unfavorable consequences bolism. In order to assess the advan­ of the loss of endogenous estradiol and tages and disadvantages of the various progesterone production. It is not of therapy regimens, it is important to primary importance to restore the know the pharmacokinetics and physiological conditions of an ovula­ metabolism of the preparation used. tory cycle, but much rather to realize Thereby it must be noted that there are the intended purpose of the treatment great inter-individual differences in ab­ in an optimal way. Various prepara­ sorption and metabolism that account tions are available for this purpose, for the individual variations in serum allowing the individual situation to be level, effects and side effects. Attention taken into account to a large extent. to the time-related differences in estro­ The choice of estrogen depends on gen levels after administration and their whether only certain complaints (e.g. accumulation or decrease during long­ atrophic symptoms) are to be treated, term application are a prerequisite for or whether the entire therapeutic and correct interpretation of the hormone preventive potential of hormone replace­ analysis, should these be considered ment therapy (HRT) is to be exploited, necessary in certain cases for monitor­ on whether bleeding will be tolerated, ing or prevention. and which side effects are acceptable. With regard to the risk of serious com­ plications, ethinyl estradiol is consid­ ered unsuitable for HRT, since the available natural estrogens estradiol, EFFECTIVENESS OF ESTROGENS estrone sulfate and estriol are suffi­ ciently effective preparations for which there are hardly any contraindications There are numerous natural and syn­ today. These preparations are supple­ thetic estrogens, all of which vary quite mented by the equine conjugated considerably in terms of their effective­ estrogens, which have a stronger effect ness (Fig. 1). The prerequisite for a strong on the hepatic metabolism than estrogenous effect is a strong binding estradiol. In the case of certain health with the estrogen receptor (Table 1), limitations (e.g. liver disorders, gastro­ whereby the resulting complex must intestinal complaints, hypertriglycerid­ have the “correct” steric configuration emia), the various alternative methods in order to remain bound to the steroid­ of application help to choose the opti­ sensitive element on the DNA for a mal therapy. Estriol, which does not sufficiently long time and to trigger the have any hepatic effects, is unsuitable biological effect. 34 Pharmacology of Estrogens and Gestagens Estradiol Estradiol valerate Estrone Estriol Equilin Dihydroequilin Equilenin Dihydroequilenin Figure 1. Structural formulas of the estrogens used in HRT Table 1. Relative binding affinities (RBA) of ent effects in the individual tissues. A some estrogens to the estrogen receptors ERα high affinity alone does not necessarily β and ER (from Kuiper et al. [1]). Since they mean a strong estrogen effect, as the depend on the incubation conditions, they are not consistent. They are not a measure of bio­ example of the anti-estrogens shows. logical effect. Moreover, the application must lead to sufficiently high concentrations in the Estrogen RBA to RBA to target cell, which depends primarily α β ER ER on the serum levels and local meta­ Estradiol-17β 100 100 bolization in the cell. Estradiol-17α 58 11 Of the physiological estrogens, Estrone 60 37 Estriol 14 21 estradiol has the strongest effect, whilst 4-hydroxyestradiol 13 7 estrone has only a slight effect due to its 2-hydroxyestradiol 7 11 low binding affinity. The significance Estrone sulfate < 1 < 1 Tamoxifen 7 6 of estrone lies in the fact that it is a 4-hydroxytamoxifen 178 339 metabolite and precursor of estradiol at Diethylstilbestrol 468 295 the same time (Fig. 2). It is conjugated Coumestrol 94 185 Genistein 5 36 into estrone sulfate, which circulates in high concentrations, and into estrone glucuronide, most of which is elimi­ Meanwhile, it has been demonstrated nated. that there are two different estrogen Estriol is a weak estrogen, which, at receptors, ERα and ERβ, which occur the normal dose, has only a low prolif­ in different concentrations in the various erative effect on the endometrium. This organs and tissues. The so-called organ­ is due to the fact that estriol is an specific effects of certain estrogens or estrogen with a short-term effect, and anti-estrogens (e.g. estriol, tamoxifene, although it is bound by the receptor raloxifene) can be explained by the fact with the same association rate as that the relevant estrogen-estrogen estradiol, it only remains bound for 1 to receptor complexes can induce differ- 4 hours due to the rapid dissociation. Pharmacology of Estrogens and Gestagens 35 As a result, the biological effects that the value of an estradiol determination rely on binding of the estrogen receptor to monitor the therapy success is doubt­ complex to the DNA for 8 to 12 hours ful. Similarly, the effectiveness of the cannot be triggered. Estriol is an end various estrogens can only be under­ product of metabolization that cannot stood as an average estimate with be transformed back into estradiol considerable individual deviations. and is also eliminated as a conjugate. Thereby, it must be noted that the ef­ Although the serum levels of the fects of the estrogens depend on the estrogens and their metabolites corre­ relevant organ or test system, so that late with the dose administered, the in­ e.g. the effect on the karyopyknotic dividual effects – like the serum levels index does not necessarily correlate on administration of the same dose – with bone density, hot flushes or he­ are very different, even if the measured patic angiotensinogen synthesis [2]. estrogen levels are identical. Accord­ In terms of their clinical effect, the ingly, the question of an optimal dose of 1 to 2 mg estradiol or estradiol estradiol level cannot be answered and valerate corresponds with a dose of 0.6 to 1.25 mg equine conjugated estrogens, which is generally consid­ ered to be the minimum effective dose 2 mg estradiol valerate for the therapy and prevention of com­ plaints and disorders caused by an Estradiol Estradiol sulfate estrogen deficiency. It is roughly com­ Day 1: 0.2 nmol/l Day 1: 0.6 nmol/l parable with a transdermal treatment Day 21: 0.3 nmol/l Day 21: 1.0 nmol/l with 100 µg estradiol [2]. By contrast, estradiol and the conju­ gated estrogens differ considerably in their effect on the hepatic metabolism Estrone Estrone sulfate (Table 2). Equine conjugated estrogens, Day 1: 1.0 nmol/l Day 1: 44 nmol/l Day 21: 1.5 nmol/l Day 21: 54 nmol/l a mixture of various estrogen conju­ gates, have a considerably stronger Figure 2. Mutual transformation of estradiol, stimulating effect on the synthesis of estrone, estrone sulfate and estradiol sulfate many proteins (e.g. angiotensinogen, during treatment with estradiol and estrone SHBG) than estradiol, which is prima­ sulfate (after Aedo et al. [4]) rily due to the equilins. In addition, oral Table 2. Relative effectiveness of certain estrogens with regard to various clinical and metabolic parameters (from Kuhl [3]). Estrogen Hot FSH HDL-CH CBG SHBG Angio­ flushes tensinogen Estradiol-17β 100 100 100 100 100 100 Estriol 30 30 20 Estrone sulfate 90 50 70 90 150 Conjugated estrogens 120 110 150 150 300 500 Equilin sulfate 600 600 750 750 Ethinyl estradiol 12,000 12,000 40,000 60,000 50,000 35,000 36 Pharmacology of Estrogens and Gestagens treatment has a stronger effect than creases, although to a far lesser degree parenteral administration due to the than estrone sulfate. The half-life of high local concentrations in the liver estradiol in the serum is around 35, that during the first passage [2]. Accordingly, of estrone around 20, that of estradiol transdermal estradiol therapy is prefer­ sulfate around 20 and that of estrone able to oral therapy in patients suffering sulfate around 12 hours [4]. Compared from severe liver function disorders or with micronized estradiol, slightly disorders of the hepatic metabolism, lower estrone levels are found after and equine conjugated estrogens administration of the same dose of should not be administered. Estriol, on estradiol valerate, although the estra­ the other hand, has no effect on the diol concentrations are similar [5]. This liver at the recommended doses. means that valerate slows down the intestinal metabolization of estradiol. In the further course of treatment with estradiol valerate, estradiol and its ESTRADIOL AND metabolites accumulate in the serum, so that on day 21 of treatment the se­ ESTRADIOL ESTER rum levels of estradiol and estrone are about 50%, that of estrone sulfate 25% and that of estradiol sulfate 65% higher Oral Administration than on day 1 (Fig. 3) [4]. In contrast to ethinyl estradiol or When administered orally, the micro­ estriol, where a rapid increase to a nized estradiol is metabolized into maximum and a similarly rapid de­ estrone, estrone sulfate and estradiol crease in serum levels is observed after sulfate to a large part in the duodenum administration, estradiol has a special and jejunum, as well as in the liver. status with regard to pharmacokinetics. Due to the large surface of the The maximum estradiol concentration microcrystals, however, a sufficient is not reached until after about 5 hours, quantity of estradiol is absorbed rap­ and the decrease is also gradual, so that idly and thus escapes metabolization. an increased estradiol level can be Similar conditions are found in treat­ found for several hours (Fig.
Recommended publications
  • PRESCRIBING INFORMATION OGEN* (Estropipate) Tablets 0.75 Mg, 1.5
    PRESCRIBING INFORMATION OGEN* (estropipate) Tablets 0.75 mg, 1.5 mg, 3.0 mg Estrogen Pfizer Canada Inc. Date of Revision: 17,300 Trans-Canada Highway 25 May 2009 Kirkland, Quebec, H9J 2M5 Control No. 120830 * TM Pharmacia Enterprises S.A. Pfizer Canada Inc., licensee © Pfizer Canada Inc., 2009 OGEN* (estropipate) Prescribing Information Page 1 of 27 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS..................................................................................................11 CLINICAL TRIAL ADVERSE DRUG REACTIONS.....................................................13 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION..............................................................................15 OVERDOSAGE ................................................................................................................16 ACTION AND CLINICAL PHARMACOLOGY ............................................................16
    [Show full text]
  • Coumestrol and Genistein
    DISSOCIATION OF UTEROTROPHIC ACTION FROM IMPLANTATION-INDUCING ACTIVITY IN TWO NON-STEROIDAL OESTROGENS (COUMESTROL AND GENISTEIN) E. PEREL and H. R. LINDNER Department of Biodynamics, Weizmann Institute of Science, Rehovot, Israel (Received 19th June 1969) Summary. The phyto-oestrogens coumestrol (7,12-dihydroxycoume- stan) and genistein (5,7,4'-trihydroxyisoflavone) induced uterine growth in ovariectomized rats, but failed to induce ovum implantation in mated ovariectomized, gestagen-maintained rats and in intact lactating rats when given at dose levels effective in uterine weight assays. Oestradiol- 17ß, under similar conditions, induced ovum implantation even at dose levels below those required for a uterine weight response. Diethyl- stilboestrol and large doses of oestradiol- 17a (5 to 10 pg) were effective in both assays. It is suggested that different uterine receptors may be involved in mediating the uterine-growth-promoting and implantation- inducing actions of oestrogen. The phyto-oestrogens coumestrol (7,12-dihydroxycoumestan) and genistein (5,7,4'-trihydroxyisoflavone) are able to mimic some of the actions of steroidal oestrogens, e.g. to stimulate uterine growth in ovariectomized mice (Bickoff, Booth, Lyman, Livingston, Thompson & DeEds, 1957; Wong & Flux, 1962) and sheep (Braden, Hart & Lamberton, 1967; Lindner, 1967; Shutt, Braden & Lindner, 1969). Another characteristic action of steroidal oestrogens is their ability to induce implantation of the dormant blastocyst in the ovariectomized, progesterone-maintained rat (Krehbiel, 1941; Canivenc & Laffargue, 1956; Shelesnyak, 1959; Mayer & Meunier, 1959; Psychoyos, 1961; Nutting & Meyer, 1963). We wished to examine whether the latter response could also be elicited, or modified, by non-steroidal oestrogens. Three-month-old Wistar-derived rats (with a body weight of 207 g ± 1 -5 S.E.) were fed unrestricted Purina Laboratory Chow (Ralston Purina Co., St.
    [Show full text]
  • Clomifene Citrate(BANM, Rinnm) ⊗
    2086 Sex Hormones and their Modulators Profasi; UK: Choragon; Ovitrelle; Pregnyl; USA: Chorex†; Choron; Gonic; who received the drug for a shorter period.6 No association be- 8. Werler MM, et al. Ovulation induction and risk of neural tube Novarel; Ovidrel; Pregnyl; Profasi; Venez.: Ovidrel; Pregnyl; Profasi†. tween gonadotrophin therapy and ovarian cancer was noted in defects. Lancet 1994; 344: 445–6. Multi-ingredient: Ger.: NeyNormin N (Revitorgan-Dilutionen N Nr this study. The conclusions of this study were only tentative, 9. Greenland S, Ackerman DL. Clomiphene citrate and neural tube 65)†; Mex.: Gonakor. defects: a pooled analysis of controlled epidemiologic studies since the numbers who developed ovarian cancer were small; it and recommendations for future studies. Fertil Steril 1995; 64: has been pointed out that a successfully achieved pregnancy may 936–41. reduce the risk of some other cancers, and that the risks and ben- 10. Whiteman D, et al. Reproductive factors, subfertility, and risk efits of the procedure are not easy to balance.7 A review8 of epi- of neural tube defects: a case-control study based on the Oxford Clomifene Citrate (BANM, rINNM) ⊗ Record Linkage Study Register. Am J Epidemiol 2000; 152: demiological and cohort studies concluded that clomifene was 823–8. Chloramiphene Citrate; Citrato de clomifeno; Clomifène, citrate not associated with any increase in the risk of ovarian cancer 11. Sørensen HT, et al. Use of clomifene during early pregnancy de; Clomifeni citras; Clomiphene Citrate (USAN); Klomifeenisi- when used for less than 12 cycles, but noted conflicting results, and risk of hypospadias: population based case-control study.
    [Show full text]
  • Download PDF File
    Ginekologia Polska 2019, vol. 90, no. 9, 520–526 Copyright © 2019 Via Medica ORIGINAL PAPER / GYNECologY ISSN 0017–0011 DOI: 10.5603/GP.2019.0091 Anti-androgenic therapy in young patients and its impact on intensity of hirsutism, acne, menstrual pain intensity and sexuality — a preliminary study Anna Fuchs, Aleksandra Matonog, Paulina Sieradzka, Joanna Pilarska, Aleksandra Hauzer, Iwona Czech, Agnieszka Drosdzol-Cop Department of Pregnancy Pathology, Department of Woman’s Health, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland ABSTRACT Objectives: Using anti-androgenic contraception is one of the methods of birth control. It also has a significant, non-con- traceptive impact on women’s body. These drugs can be used in various endocrinological disorders, because of their ability to reduce the level of male hormones. The aim of our study is to establish a correlation between taking different types of anti-androgenic drugs and intensity of hirsutism, acne, menstrual pain intensity and sexuality . Material and methods: 570 women in childbearing age that had been using oral contraception for at least three months took part in our research. We examined women and asked them about quality of life, health, direct causes and effects of that treatment, intensity of acne and menstrual pain before and after. Our research group has been divided according to the type of gestagen contained in the contraceptive pill: dienogest, cyproterone, chlormadynone and drospirenone. Ad- ditionally, the control group consisted of women taking oral contraceptives without antiandrogenic component. Results: The mean age of the studied group was 23 years ± 3.23. 225 of 570 women complained of hirsutism.
    [Show full text]
  • A Guide to Feminizing Hormones – Estrogen
    1 | Feminizing Hormones ​ ​ A Guide to Feminizing Hormones Hormone therapy is an option that can help transgender and gender-diverse people feel more comfortable in their bodies. Like other medical treatments, there are benefits and risks. Knowing what to expect will help us work together to maximize the benefits and minimize the risks. What are hormones? Hormones are chemical messengers that tell the body’s cells how to function, ​ when to grow, when to divide, and when to die. They regulate many functions, including growth, sex drive, hunger, thirst, digestion, metabolism, fat burning & storage, blood sugar, cholesterol levels, and reproduction. What are sex hormones? Sex hormones regulate the development of sex characteristics, including the sex ​ organs such as genitals and ovaries/testicles. Sex hormones also affect the secondary sex characteristics that typically develop at puberty, like facial and body hair, bone growth, breast growth, and voice changes. There are three categories of sex hormones in the body: • Androgens: testosterone, dehydroepiandrosterone (DHEA), ​ dihydrotestosterone (DHT) • Estrogens: estradiol, estriol, estrone ​ • Progestin: progesterone ​ Generally, “males” tend to have higher androgen levels, and “females” tend to have higher levels of estrogens and progestogens. What is hormone therapy? Hormone therapy is taking medicine to change the levels of sex hormones in your body. Changing these levels will affect your hair growth, voice pitch, fat distribution, muscle mass, and other features associated with sex and gender. Feminizing hormone therapy can help make the body look and feel less “masculine” and more “feminine" — making your body more closely match your identity. What medicines are involved? There are different kinds of medicines used to change the levels of sex hormones in your body.
    [Show full text]
  • 232383538.Pdf
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Groningen University of Groningen X-ray Structure of Cyclodextrin Glycosyltransferase Complexed with Acarbose. Implications for the Catalytic Mechanism of Glycosidases STROKOPYTOV, B; PENNINGA, D; ROZEBOOM, HJ; KALK, KH; DIJKHUIZEN, L; DIJKSTRA, BW Published in: Biochemistry DOI: 10.1021/bi00007a018 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 1995 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): STROKOPYTOV, B., PENNINGA, D., ROZEBOOM, HJ., KALK, KH., DIJKHUIZEN, L., & DIJKSTRA, BW. (1995). X-ray Structure of Cyclodextrin Glycosyltransferase Complexed with Acarbose. Implications for the Catalytic Mechanism of Glycosidases. Biochemistry, 34(7), 2234-2240. https://doi.org/10.1021/bi00007a018 Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
    [Show full text]
  • Mass Spectrometry Analysis of Hormones in Water by Direct Injection
    Application Note Environmental Mass Spectrometry Analysis of Hormones in Water by Direct Injection Using the Agilent 6470 Triple Quadrupole Mass Spectrometer Authors Abstract Imma Ferrer, E. Michael Thurman, and Some hormones are included in the Contaminant Candidate List CCL4 of the Jerry A. Zweigenbaum Environmental Protection Agency (EPA) to be assessed for regulation in drinking University of Colorado and water. These compounds are also of regulatory interest in the EU, China, and other Agilent Technologies, Inc. countries. Therefore, the environmental community often desires the analysis of these compounds in water samples. This Application Note describes the methodology used for the determination of eight hormones (17-α-ethinylestradiol, 17-β-estradiol, estriol, 4-androstene-3,17-dione, equilin, estrone, progesterone, and testosterone) in tap water using an Agilent 6470 triple quadrupole mass spectrometer. A direct injection method using 100 µL of water sample was carried out. This method saves time, reduces handling errors and analytical variability, and is sensitive enough to detect hormones in surface and drinking water at ng/L levels. Introduction Both positive and negative ion modes and stored at −18 °C. A mix of all were used, depending on the specific the hormones was prepared at a The presence of hormones in compound. We also used a novel concentration of 1 μg/mL. Serial dilutions environmental waters has always been mobile phase approach that included were prepared to obtain a calibration controversial because either none have ammonium fluoride to enhance the curve ranging from 1 to 500 ng/L. been detected, or very low traces have negative ion signal4.
    [Show full text]
  • Chemical Compounds As Carcinogenic Agents Second Supplementary Report: Literature of 1938 and 1939 Biological Considerations
    CHEMICAL COMPOUNDS AS CARCINOGENIC AGENTS SECONDSUPPLEMENTARY REPORT: LITERATURE OF 1938 AND 1939 J. W. COOK AND E. L. KENNAWAY (From the Royal Cancer Hospital (Free), London, and the University of Glasgow) BIOLOGICALCONSIDERATIONS (Continued from page 428, Jitly 1940) II. Action of Carcinogenic Compounds in Difierent Species and Tissues A number of reports of the action of carcinogenic compounds on human tis- sues have appeared. Klar (601) developed a nodule on the forearm after completion of a series of experiments with 3:4-benzpyrene. He applied a solution of the hydrocarbon (0.25 per cent in benzol) to the skin of mice with a paint brush and for at least part of the period wore rubber gloves. He also conducted experiments, of which no description is given, with the powdered hydrocarbon contained in a glass vessel. Three months after the completion of the experiments a small nodule appeared on the dorsum of the left forearm, This was excised in May 1938 and described by Professor Huckel as a “ so- called benign calcifying epithelioma.” The growth extended into the subcu- taneous fatty tissue; the connection with the superficial epithelium is not described nor is it evident in the two photomicrographs which illustrate the report. The author does not state his age. Gordonoff and Walthard (562) record the occurrence of a tumor in a labo- ratory assistant, aged forty-two, engaged in applying methylcholanthrene (0.3 per cent in benzol) to the skin of mice. The site was in the nasolabial fold, at a spot often touched by the patient when smoking. The microscopic ap- pearance was that of a “ still well delimited stage of an incipient squamous- cell sarcoma.” Cottini and Mazzone (479) deliberately applied 3 :4-benzpyrene ( 1 per cent in benzene) to the skin, generally of the arm or thigh, of 26 patients with various cutaneous diseases, usually daily for periods up to 120 days.
    [Show full text]
  • Antiestrogenic Action of Dihydrotestosterone in Mouse Breast
    Antiestrogenic action of dihydrotestosterone in mouse breast. Competition with estradiol for binding to the estrogen receptor. R W Casey, J D Wilson J Clin Invest. 1984;74(6):2272-2278. https://doi.org/10.1172/JCI111654. Research Article Feminization in men occurs when the effective ratio of androgen to estrogen is lowered. Since sufficient estrogen is produced in normal men to induce breast enlargement in the absence of adequate amounts of circulating androgens, it has been generally assumed that androgens exert an antiestrogenic action to prevent feminization in normal men. We examined the mechanisms of this effect of androgens in the mouse breast. Administration of estradiol via silastic implants to castrated virgin CBA/J female mice results in a doubling in dry weight and DNA content of the breast. The effect of estradiol can be inhibited by implantation of 17 beta-hydroxy-5 alpha-androstan-3-one (dihydrotestosterone), whereas dihydrotestosterone alone had no effect on breast growth. Estradiol administration also enhances the level of progesterone receptor in mouse breast. Within 4 d of castration, the progesterone receptor virtually disappears and estradiol treatment causes a twofold increase above the level in intact animals. Dihydrotestosterone does not compete for binding to the progesterone receptor, but it does inhibit estrogen-mediated increases of progesterone receptor content of breast tissue cytosol from both control mice and mice with X-linked testicular feminization (tfm)/Y. Since tfm/Y mice lack a functional androgen receptor, we conclude that this antiestrogenic action of androgen is not mediated by the androgen receptor. Dihydrotestosterone competes with estradiol for binding to the cytosolic estrogen receptor of mouse breast, […] Find the latest version: https://jci.me/111654/pdf Antiestrogenic Action of Dihydrotestosterone in Mouse Breast Competition with Estradiol for Binding to the Estrogen Receptor Richard W.
    [Show full text]
  • Estradiol-17Β Pharmacokinetics and Histological Assessment Of
    animals Article Estradiol-17β Pharmacokinetics and Histological Assessment of the Ovaries and Uterine Horns following Intramuscular Administration of Estradiol Cypionate in Feral Cats Timothy H. Hyndman 1,* , Kelly L. Algar 1, Andrew P. Woodward 2, Flaminia Coiacetto 1 , Jordan O. Hampton 1,2 , Donald Nickels 3, Neil Hamilton 4, Anne Barnes 1 and David Algar 4 1 School of Veterinary Medicine, Murdoch University, Murdoch 6150, Australia; [email protected] (K.L.A.); [email protected] (F.C.); [email protected] (J.O.H.); [email protected] (A.B.) 2 Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Melbourne 3030, Australia; [email protected] 3 Lancelin Veterinary Hospital, Lancelin 6044, Australia; [email protected] 4 Department of Biodiversity, Conservation and Attractions, Locked Bag 104, Bentley Delivery Centre 6983, Australia; [email protected] (N.H.); [email protected] (D.A.) * Correspondence: [email protected] Received: 7 September 2020; Accepted: 17 September 2020; Published: 21 September 2020 Simple Summary: Feral cats (Felis catus) have a devastating impact on Australian native fauna. Several programs exist to control their numbers through lethal removal, using tools such as baiting with toxins. Adult male cats are especially difficult to control. We hypothesized that one way to capture these male cats is to lure them using female cats. As female cats are seasonal breeders, a method is needed to artificially induce reproductive (estrous) behavior so that they could be used for this purpose year-round (i.e., regardless of season).
    [Show full text]
  • How to Select Pharmacologic Treatments to Manage Recidivism Risk in Sex Off Enders
    How to select pharmacologic treatments to manage recidivism risk in sex off enders Consider patient factors when choosing off -label hormonal and nonhormonal agents ® Dowden Healthex offenders Media traditionally are managed by the criminal justice system, but psychiatrists are fre- Squently called on to assess and treat these indi- CopyrightFor personalviduals. use Part only of the reason is the overlap of paraphilias (disorders of sexual preference) and sexual offending. Many sexual offenders do not meet DSM criteria for paraphilias,1 however, and individuals with paraphil- ias do not necessarily commit offenses or come into contact with the legal system. As clinicians, we may need to assess and treat a wide range of sexual issues, from persons with paraphilias who are self-referred and have no legal involvement, to recurrent sexual offenders who are at a high risk of repeat offending. Successfully managing sex offenders includes psychological and pharmacologic interven- 2009 © CORBIS / TIM PANNELL 2009 © CORBIS / tions and possibly incarceration and post-incarceration Bradley D. Booth, MD surveillance. This article focuses on pharmacologic in- Assistant professor terventions for male sexual offenders. Department of psychiatry Director of education Integrated Forensics Program University of Ottawa Reducing sexual drive Ottawa, ON, Canada Sex offending likely is the result of a complex inter- play of environment and psychological and biologic factors. The biology of sexual function provides nu- merous targets for pharmacologic intervention, in- cluding:2 • endocrine factors, such as testosterone • neurotransmitters, such as serotonin. The use of pharmacologic treatments for sex of- fenders is off-label, and evidence is limited. In general, Current Psychiatry 60 October 2009 pharmacologic treatments are geared toward reducing For mass reproduction, content licensing and permissions contact Dowden Health Media.
    [Show full text]
  • Bazedoxifene–Conjugated Estrogens for Treating Endometriosis Endometriosis: Nina S
    Endometriosis: Case Report Bazedoxifene–Conjugated Estrogens Teaching Points for Treating Endometriosis 1. The estrogen receptor (ER) is a definitive down- stream target in endometriosis. As an endometrial ER antagonist, bazedoxifene assures not only block- Valerie A. Flores, MD, ade of estrogen binding, but it also has the ability to Nina S. Stachenfeld, PhD, degrade the receptor. This unique property of baze- and Hugh S. Taylor, MD doxifene blocks estrogen action and makes it an attractive treatment option for endometriosis. 2. Conjugated estrogens paired with bazedoxifene do BACKGROUND: Endometriosis is a gynecologic disorder not require a progestin to block endometrial affecting 6–10% of reproductive-aged women. First-line growth, thus avoiding the side effects associated therapies are progestin-based regimens; however, failure with progestin-based regimens. 08/19/2018 on BhDMf5ePHKbH4TTImqenVGLGjjqParD6K7Nl5tTGGFqgjMmLRmuIlIgbkUbgVXoQ by http://journals.lww.com/greenjournal from Downloaded rates are high, often requiring alternative hormonal agents, each with unfavorable side effects. Bazedoxifene with con- ’ 1 Downloaded that can have a significant effect on patients lives. jugated estrogens is approved for treatment of menopausal Treatment consists of agents that induce atrophy of symptoms, and use in animal studies has demonstrated from regression of endometriotic lesions. As such, it represents endometriotic lesions. There is tremendous need for http://journals.lww.com/greenjournal a potential treatment option for endometriosis. therapies that are effective, have favorable side effect profiles, and can be used long term in women with CASE: A patient with stage III endometriosis referred for symptomatic endometriosis, especially for those not management of dysmenorrhea and cyclic pelvic pain was treated with 20 mg bazedoxifene and 0.45 mg conjugated responding to progestin-based regimens.
    [Show full text]